Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study by McArthur, Grant A, Prof, Chapman, Paul B, Prof, Robert, Caroline, MD, Larkin, James, MD, Haanen, John B, MD, Dummer, Reinhard, Prof, Ribas, Antoni, Prof, Hogg, David, Prof, Hamid, Omid, MD, Ascierto, Paolo A, MD, Garbe, Claus, Prof, Testori, Alessandro, MD, Maio, Michele, MD, Lorigan, Paul, MD, Lebbé, Celeste, Prof, Jouary, Thomas, MD, Schadendorf, Dirk, Prof, O'Day, Stephen J, MD, Kirkwood, John M., Prof, Eggermont, Alexander M, Prof, Dréno, Brigitte, Prof, Sosman, Jeffrey A, Prof, Flaherty, Keith T, MD, Yin, Ming, PhD, Caro, Ivor, MD, Cheng, Suzanne, PhD, Trunzer, Kerstin, PhD, Hauschild, Axel, Prof

Get full text

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial by Ribas, Antoni, Prof, Puzanov, Igor, MD, Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Hamid, Omid, MD, Robert, Caroline, Prof, Hodi, F Stephen, MD, Schachter, Jacob, Prof, Pavlick, Anna C, MD, Lewis, Karl D, MD, Cranmer, Lee D, MD, Blank, Christian U, MD, O'Day, Steven J, MD, Ascierto, Paolo A, Prof, Salama, April K S, MD, Margolin, Kim A, Prof, Loquai, Carmen, MD, Eigentler, Thomas K, MD, Gangadhar, Tara C, MD, Carlino, Matteo S, MBBS, Agarwala, Sanjiv S, Prof, Moschos, Stergios J, MD, Sosman, Jeffrey A, Prof, Goldinger, Simone M, MD, Shapira-Frommer, Ronnie, MD, Gonzalez, Rene, Prof, Kirkwood, John M, Prof, Wolchok, Jedd D, Prof, Eggermont, Alexander, Prof, Li, Xiaoyun Nicole, PhD, Zhou, Wei, PhD, Zernhelt, Adriane M, BS, Lis, Joy, BSN, Ebbinghaus, Scot, MD, Kang, S Peter, MD, Daud, Adil, Prof

Get full text

First Applications of the Joint Forces Command Information Operations Range - An ACETEF Perspective by O'Day, Stephen C, Bonnevier, Kirk J, Kropp, Derek L, Morrison, Michael R, Freed, Mark R

Request full text